XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
segment
Jun. 30, 2020
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2016
USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]                
Restricted cash $ 100,000   $ 100,000     $ 100,000    
Joint venture quarterly promotion fee cap 10.00%   10.00%   10.00%      
Revenue $ 12,772,000 $ 8,948,000 $ 23,359,000 $ 18,532,000        
Advertising expense 400,000 300,000 $ 600,000 700,000        
Dividend yield     0.00%          
Number of operating segments | segment     1          
Janssen Promotion Agreement                
New Accounting Pronouncement, Early Adoption [Line Items]                
Termination of agreement 600,000   $ 600,000          
Janssen (SIMPONI)                
New Accounting Pronouncement, Early Adoption [Line Items]                
Revenue 300,000 2,100,000 600,000 2,100,000        
Minimum                
New Accounting Pronouncement, Early Adoption [Line Items]                
Joint venture, quarterly promotion fee per prescription 500 750 500 750 $ 500   $ 750  
Joint venture, quarterly promotion fee 300,000   300,000   300,000      
Maximum                
New Accounting Pronouncement, Early Adoption [Line Items]                
Joint venture, quarterly promotion fee per prescription 1,000 1,250 1,000 1,250 $ 1,000   $ 1,250  
Other assets                
New Accounting Pronouncement, Early Adoption [Line Items]                
Restricted cash               $ 100,000
Shipping and Handling                
New Accounting Pronouncement, Early Adoption [Line Items]                
Cost of revenue $ 600,000 $ 300,000 $ 1,000,000.0 $ 700,000        
Revenue Benchmark | Product Concentration Risk | AVISE CTD Test                
New Accounting Pronouncement, Early Adoption [Line Items]                
Percent of total revenue 81.00% 60.00% 81.00% 72.00%        
Revenue Benchmark | Supplier Concentration Risk | Two Major Suppliers                
New Accounting Pronouncement, Early Adoption [Line Items]                
Percent of total revenue 97.00% 97.00% 97.00% 97.00%